ESR1 and cancer: This type of treatment targets estrogen-dependent cancers via selective ER modulators (SERMs) (tamoxifen) or ER degraders (SERDs) (fulvestrant), or interferes with the production of estrogen via aromatase inhibitors [22,23,24].